Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Voyager Therapeutics Inc (VYGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8306)・商品コード:DATA904C8306
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its clinical candidate, VY-AADC, currently under open-label Phase 1b clinical trials, is intended for the treatment of advanced Parkinson’s disease. Voyager’s preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington’s disease; VY-FXN01 for Friedreich’s ataxia; Tau program, for tauopathies including Alzheimer’s disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company offers development services in the areas such as vector optimization and engineering, dosing techniques, and process development and production, among others. Voyager is headquartered in Cambridge, Massachusetts, the US.

Voyager Therapeutics Inc (VYGR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Voyager Therapeutics Raises USD60 Million in Series B Financing 12
Voyager Therapeutics Raises US$45 Million In Series A Financing 13
Partnerships 14
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 14
Voyager Therapeutics Enters into Research Agreement with CHDI Foundation 16
Voyager Therapeutics Enters into Development Agreement with Genzyme 17
Voyager Therapeutics Enters into Agreement with MassBiologics 18
Licensing Agreements 19
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 19
Voyager Therapeutics Enters into Licensing Agreement with California Institute of Technology 20
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 21
Voyager Therapeutics Enters Into Licensing Agreement With University Of Massachusetts 23
Equity Offering 25
Voyager Therapeutics Raises USD62.1 Million in Public Offering of Shares 25
Voyager Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 27
Voyager Therapeutics Raises USD80.5 Million in IPO 28
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 30
Voyager Therapeutics Inc – Key Competitors 31
Voyager Therapeutics Inc – Key Employees 32
Voyager Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 07, 2018: Voyager Therapeutics announces second quarter 2018 financial results and corporate highlights 34
May 10, 2018: Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights 36
Mar 14, 2018: Voyager Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 38
Nov 02, 2017: Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights 40
Aug 08, 2017: Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights 43
May 09, 2017: Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights 46
Mar 15, 2017: Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights 48
Corporate Communications 51
Jun 28, 2018: Voyager Therapeutics Names Andre Turenne As President And Chief Executive Officer 51
May 29, 2018: Voyager Therapeutics Announces Management Change 53
Jan 31, 2018: Voyager Therapeutics Announces CEO Succession Plan for 2018 54
Sep 18, 2017: Voyager Therapeutics Appoints Matthew P. Ottmer as Chief Operating Officer 55
Jan 05, 2017: Voyager Therapeutics Elects Wendy Dixon, Ph.D. and Glenn Pierce, M.D., Ph.D. to Board of Directors 56
Jan 03, 2017: Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer 57
Product News 58
10/16/2018: Voyager Therapeutics announces preclinical data for Amyotrophic Lateral Sclerosis at the Congress of the European Society of Gene and Cell Therapy 58
Jul 17, 2017: Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain 59
02/13/2017: Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS) 60
Clinical Trials 61
May 17, 2018: Voyager Therapeutics Announces New Data on VY-SOD101 at the American Society of Gene and Cell Therapy 2018 Annual Meeting 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Voyager Therapeutics Raises USD60 Million in Series B Financing 12
Voyager Therapeutics Raises US$45 Million In Series A Financing 13
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 14
Voyager Therapeutics Enters into Research Agreement with CHDI Foundation 16
Voyager Therapeutics Enters into Development Agreement with Genzyme 17
Voyager Therapeutics Enters into Agreement with MassBiologics 18
RegenxBio Exercises its Option Agreement with Voyager Therapeutics 19
Voyager Therapeutics Enters into Licensing Agreement with California Institute of Technology 20
Voyager Therapeutics Enters into Licensing Agreement with ReGenX Biosciences 21
Voyager Therapeutics Enters Into Licensing Agreement With University Of Massachusetts 23
Voyager Therapeutics Raises USD62.1 Million in Public Offering of Shares 25
Voyager Therapeutics Plans to Raise up to USD75 Million in Public Offering of Shares 27
Voyager Therapeutics Raises USD80.5 Million in IPO 28
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 30
Voyager Therapeutics Inc, Key Competitors 31
Voyager Therapeutics Inc, Key Employees 32
Voyager Therapeutics Inc, Subsidiaries 33

List of Figures
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Voyager Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Voyager Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8306)販売に関する免責事項を必ずご確認ください。
★調査レポート[Voyager Therapeutics Inc (VYGR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆